EP0299057A4 - Augmentation de la puissance de conjugues cytotoxiques. - Google Patents

Augmentation de la puissance de conjugues cytotoxiques.

Info

Publication number
EP0299057A4
EP0299057A4 EP19880901988 EP88901988A EP0299057A4 EP 0299057 A4 EP0299057 A4 EP 0299057A4 EP 19880901988 EP19880901988 EP 19880901988 EP 88901988 A EP88901988 A EP 88901988A EP 0299057 A4 EP0299057 A4 EP 0299057A4
Authority
EP
European Patent Office
Prior art keywords
potentiation
cytotoxic conjugates
conjugates
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880901988
Other languages
German (de)
English (en)
Other versions
EP0299057A1 (fr
Inventor
Vera S Byers
Robert W Baldwin
Patrick J Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of EP0299057A1 publication Critical patent/EP0299057A1/fr
Publication of EP0299057A4 publication Critical patent/EP0299057A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP19880901988 1987-01-27 1988-01-26 Augmentation de la puissance de conjugues cytotoxiques. Withdrawn EP0299057A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US704587A 1987-01-27 1987-01-27
US7045 1987-01-27

Publications (2)

Publication Number Publication Date
EP0299057A1 EP0299057A1 (fr) 1989-01-18
EP0299057A4 true EP0299057A4 (fr) 1990-02-22

Family

ID=21723902

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880901988 Withdrawn EP0299057A4 (fr) 1987-01-27 1988-01-26 Augmentation de la puissance de conjugues cytotoxiques.

Country Status (4)

Country Link
EP (1) EP0299057A4 (fr)
JP (1) JPH01502195A (fr)
KR (1) KR890700357A (fr)
WO (1) WO1988005309A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
US5173293A (en) * 1989-02-23 1992-12-22 Becton Dickinson And Company Anti-T-cell antibodies as adjuvants
CA2065048A1 (fr) * 1990-06-29 1991-12-30 Shojiro Yamazaki Immunotoxine conjuguee
WO1994007138A1 (fr) 1992-09-14 1994-03-31 Fodstad Oystein Detection de cellules cibles specifiques dans une population de cellules specialisees ou mixtes et solutions contenant des populations de cellules mixtes
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811075B2 (ja) * 1982-06-30 1996-02-07 雄治 松岡 単クローン性抗ｃｅａ抗体
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYBRIDOMA, vol. 5, no. 3, 1986, pages 199-213, Mary Ann Liebert, Inc., Publishers; R. WELLERSON et al.: "Enhanced binding activity observed between anti-carcinoembryonic monoclonal antibodies" *
See also references of WO8805309A1 *

Also Published As

Publication number Publication date
JPH01502195A (ja) 1989-08-03
KR890700357A (ko) 1989-04-24
WO1988005309A1 (fr) 1988-07-28
EP0299057A1 (fr) 1989-01-18

Similar Documents

Publication Publication Date Title
ZA895909B (en) Cytotoxic drug conjugates
EP0276121A3 (en) Wavelength-specific cytotoxic agents
ZA895908B (en) Cytotoxic drug conjugates
PH31059A (en) Pharmaceutical compositions comprising cyclosporins.
HUT53126A (en) Antibody medicament conjugates
OA08741A (en) N-phenylpyrazol derivatives.
JPS6479146A (en) Drug composition
AU2201888A (en) Pharmaceutical combination
EP0299057A4 (fr) Augmentation de la puissance de conjugues cytotoxiques.
EP0338092A4 (fr) Agent anti-vih.
EP0300036A4 (fr) Compositions pharmaceutiques a base de vasopressine.
EP0305902A3 (en) Medicament
IE892534L (en) Cytotoxic drug conjugates
IE892533L (en) Cytotoxic drug conjugates
GB2213062B (en) Pharmaceutical preparation having oestrogen action.
ZA917789B (en) Pharmaceutical preparation.
IE872452L (en) Pharmaceutical formulations.
NO904235D0 (no) Forbedret cytotoksisk terapi.
DE3882331D1 (en) Dose.
AU2600688A (en) Oligonucleotide-polyamide conjugates
IE871070L (en) Ergolene derivatives.
IE870257L (en) Erythromycylamine derivatives.
IE871476L (en) Ó-ketonitrone derivatives.
IE873402L (en) Alkanesulphonanilide derivatives.
IE883489L (en) Drug-monoclonalantibody conjugates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19881219

A4 Supplementary search report drawn up and despatched

Effective date: 19900222

17Q First examination report despatched

Effective date: 19920331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19940425